Shilpa Medicare has received a tentative approval for its ANDA , Bortezomib for Injection, 3.5mg/vial from the USFDA. Bortezomib for Injection, 3.5mg/vial is a generic equivalent of reference listed drug (RLD), VELCADE used in the treatment of patients with multiple myeloma and Mantle Cell Lymphoma as recommended in the label approved by the FDA.According to IQVIA MAT Q4 2018 data, the US market for Bortezomib for Injection, 3.5mg/vial is approximately US$609 million.